SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Transkaryotic Therapies (TKTX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: paradigm7241 who wrote (2)4/21/2000 1:17:00 PM
From: david james   of 12
 
I believe that Amgen's method is substantially quite different from that of TKTX and therefore should not be covered in the Amgen patent. However, the real question is whether Amgen can keep up the legal proceedings for several years and effectively block TKTXs product from getting to market. In three years or so, I believe Amgen's patent runs out anyway. So the question to me is how long Amgen can stall.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News